BLRX: BioLineRx Ltd Short-Term Debt to Equity

BioLineRx Ltd. - graphic logo of issuer BLRX

Israeli developer BioLineRx Ltd. (BLRX) has established its market presence through Aphexda, which received FDA approval and has been integrated into US oncology centers. This chart of the debt-to-equity ratio stands at 0.36. The company balances the sale of finished pharmaceuticals with new research to diversify its portfolio, while international partnerships and Western patents minimize the impact of regional instability on the business.

BLRX (BioLineRx Corp) Current Liabilities to Capital history from 07/04/2022 to 10/28/2026

Analytical breakdowns for biolinerx.com (BLRX)

- price and consensus price forecast:
Stock Price BioLineRx Corp|BLRX - Average Forecast Price
- market capitalization data:
Market Value BioLineRx Ltd|BLRX - Business Value
- book capitalization data:
Book Value per Share BioLineRx|BLRX - Total Stockholders' Equity|Market Value to Book Value Ratio biolinerx.com|BLRX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital BioLineRx Ltd.|BLRX - Long-Term Debt to Capital|Short-Term Debt to Equity BioLineRx|BLRX - Company Debts|Debt to Book Value BioLineRx Ltd
Fundamental company analysis:BioLineRx Ltd.
Brand item of BioLineRx

Investors are evaluating BioLineRx Ltd. (BLRX) through the lens of capital-intensive R&D developments in peptide platforms for oncology therapy. By analyzing the ratio of short-term debt to equity, one can determine the proportion of liabilities maturing within one year relative to shareholders' equity, where a declining coefficient confirms high financial autonomy and the company's ability to independently fund scientific innovations without liquidity risk.

Competing companies

Incyte Corp. - Short-Term Debt to Capital|Current Liabilities to Capital HCM (HUTCHMED Corp)|NUVB - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio dayonebio.com DAWN|MNPR (Monopar Therapeutics Inc.) - Short-Term Debt to Capital|INBX: Current Liabilities to Capital|Short-Term Debt to Equity i-mabbiopharma.com IMAB|Fennec (FENC) - Ratio of Short-Term Indebtedness to Capital|HRTX (Heron) - Short-Term Debt to Capital|Short-Term Debt to Capital NVCT|Short-Term Debt to Equity Coherus BioSciences, Inc (CHRS)|Short-Term Debt to Equity Corbus Pharmaceuticals Holdings, Inc. CRBP|Short-Term Debt to Equity Ratio Cardiff Oncology|BeyondSpring Inc - Ratio of Short-Term Indebtedness to Capital|BCAB (BioAtla Corp) - Short-Term Debt to Equity|LIXT: Current Liabilities to Capital|Short-Term Debt to Equity citiuspharma.com|Cellectar Biosciences Inc (CLRB) - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CANF|Short-Term Debt to Equity Ratio APRE|Kazia Therapeutics - Short-Term Debt to Equity|Current Liabilities to Capital SLXN (silexion.com)|Short-Term Debt to Equity NuCana NCNA|Chimerix Inc. - Short-Term Debt to Equity|CYCC (Cyclacel Pharmaceuticals Inc.) - Short-Term Debt to Equity|GTHX - Current Liabilities to Capital|Short-Term Debt to Capital KRON (Kronos Bio, Inc.)|Short-Term Indebtedness to Equity kintara.com|Short-Term Debt to Equity Ratio ONCT (Oncternal Therapeutics, Inc.)|Current Liabilities to Capital Portage Biotech Inc (PRTG)